Free shipping on all orders over $ 500

Riviciclib hydrochloride (P276-00)

Cat. No. M2911
Riviciclib hydrochloride (P276-00)  Structure

Riviciclib hydrochloride

Size Price Availability
5mg USD 198  USD198 Out of stock
10mg USD 325  USD325 Out of stock
50mg USD 940  USD940 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Riviciclib hydrochloride (P276-00) is an effective CDK inhibitor, inhibiting CDK9-CyclinT1, CDK4-cyclin D1, CDK1-Cyclinb with IC50 values of 20 nM, 63 nM, respectively. 79 nM. Riviciclib hydrochloride (P276-00) has anti-tumor activity against Cisplatin resistant cells.

Chemical Information
Molecular Weight 438.3
Formula C21H20ClNO5.HCl
CAS Number 920113-03-7
Solubility (25°C) DMSO 70 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Shirsath NP, et al. Mol Cancer. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

[2] Joshi KS, et al. Mol Cancer Ther. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

Related CDK Products

QR-6401 is a a highly potent and selective macrocyclic CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.


FN-1501 is a potent inhibitor of Fms-like receptor tyrosine kinase 3 (FLT3) and cyclin-dependent kinase (CDK), and the IC50 for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3 with IC50s of 2.47, 0.85, 1.96 and 0.28 nM, respectively.


DS96432529 is a potent bone anabolic agent with oral activity and CDK8 inhibitory activity.


The CDK7 kinase inhibitor SY-5609 is a picomolar, reversible, highly selective molecule with slow off-rate kinetics. SY-5609 has a weak inhibitory effect on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), and CDK12 (Ki=870 nM).


AS-0141 (Cdc7-IN-6) is a potent Cdc7 kinase inhibitor (IC50=4 nM) with antitumor activity as described in WO2019165473A1, compound I-D. Cdc7 is a serine threonine protein kinase enzyme that is essential for the initiation of DNA replication during the cell cycle.

Abmole Inhibitor Catalog

Keywords: Riviciclib hydrochloride (P276-00) , Riviciclib hydrochloride supplier, CDK, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.